Ironwood Financial’s Corbus Pharmaceuticals CRBP Stock Holding History

Ironwood Financial’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1	Closed	–	–	560
2021 Q1	$0	Buy	+1	New	+$66	﹤0.01%	542

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Ironwood Financial's CRBP Position: Q2 2021 in Review

Ironwood Financial sold out of Corbus Pharmaceuticals (CRBP) in Q2 2021, closing a stake of 1 share.

Ironwood Financial first reported a position in CRBP in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 98 funds tracked by Wall St. Rank hold CRBP as of Q2 2021.

Ironwood Financial reported no remaining Corbus Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Ironwood Financial sold 1 Corbus Pharmaceuticals share in Q2 2021.
Ironwood Financial first reported a position in Corbus Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Ironwood Financial's Corbus Pharmaceuticals position peaked at $0 in Q1 2021.
98 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2021.

Based on Ironwood Financial's 13F filing for Q2 2021, filed 29 Jul 2021.